<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25372468</article-id><article-id pub-id-type="pmc">4221197</article-id><article-id pub-id-type="publisher-id">PONE-D-14-34863</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0111886</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Engineering and Technology</subject><subj-group><subject>Management Engineering</subject><subj-group><subject>Decision Analysis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Research and Analysis Methods</subject></subj-group></article-categories><title-group><article-title>An Elevated Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Favorable Response and Prognosis in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy</article-title><alt-title alt-title-type="running-head">LMR Ratio Predicts Favorable Response and Prognosis in LABC</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ni</surname><given-names>Xiao-Jian</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Xiao-Lan</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ou-Yang</surname><given-names>Qian-Wen</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Qian</surname><given-names>Guo-Wei</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Sheng</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Yi-Zhou</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zuo</surname><given-names>Wen-Jia</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jiong</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shao</surname><given-names>Zhi-Ming</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Institutes of Biomedical Science, Fudan University, Shanghai, China</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Changzhou No 2 People&#x02019;s Hospital Affiliated to Nanjing Medical University, Jiangsu, China</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Department of Breast Surgery, the Third Hospital of Nanchang, Nanchang, Jiangxi, China</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Guan</surname><given-names>Xin-Yuan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>The University of Hong Kong, China</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>zhi_ming_shao@163.com</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: XJN ZMS. Performed the experiments: XLZ QWOY. Analyzed the data: GWQ LW. Contributed reagents/materials/analysis tools: SC YZJ. Contributed to the writing of the manuscript: XJN WJZ JW XH.</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>5</day><month>11</month><year>2014</year></pub-date><volume>9</volume><issue>11</issue><elocation-id>e111886</elocation-id><history><date date-type="received"><day>3</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Ni et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Ni et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>Neoadjuvant chemotherapy (NCT) is a standard treatment option for locally advanced breast cancer. However, the lack of an efficient method to predict treatment response and patient prognosis hampers the clinical evaluation of patient eligibility for NCT. An elevated lymphocyte-to-monocyte ratio (LMR) has been reported to be associated with a favorable prognosis for certain hematologic malignancies and for nasopharyngeal carcinoma; however, this association has not been investigated in breast cancer. The purpose of this study was to evaluate whether pre-NCT LMR analysis could predict the prognosis of patients with locally advanced breast cancer.</p></sec><sec><title>Methods</title><p>A retrospective cohort of 542 locally advanced breast cancer patients (T3/T4 and/or N2/N3 disease) receiving NCT followed by radical surgery was recruited between May 2002 and August 2011 at the Fudan University Shanghai Cancer Center. Counts for pre-NCT peripheral absolute lymphocytes and monocytes were obtained and used to calculate the LMR.</p></sec><sec><title>Results</title><p>Univariate and multivariate analysis revealed that higher LMR levels (&#x02265;4.25) were significantly associated with favorable DFS (<italic>P</italic>&#x0200a;=&#x0200a;0.009 and <italic>P</italic>&#x0200a;=&#x0200a;0.011, respectively). Additionally, univariate analysis revealed that a higher lymphocyte count (&#x02265;1.5&#x000d7;10<sup>9</sup>/L) showed borderline significance for improved DFS (<italic>P</italic>&#x0200a;=&#x0200a;0.054), while a lower monocyte count (&#x0003c;0.4&#x000d7;10<sup>9</sup>/L) was associated with a significantly better DFS (<italic>P</italic>&#x0200a;=&#x0200a;0.010).</p></sec><sec><title>Conclusions</title><p>An elevated pre-NCT peripheral LMR level was a significantly favorable factor for locally advanced breast cancer patient prognosis. This easily obtained variable may serve as a valuable marker to predict the outcomes of locally advanced breast cancer.</p></sec></abstract><funding-group><funding-statement>The study was supported by grants from the National Natural Science Foundation of China (81201531), the 2012 Shanghai Committee of Science and Technology Funds (12ZR1406200, 12DZ2260100 and 12140901502) and the Shanghai Committee of Science and Technology Fund for 2013 Qimingxing Project (11QA1401400 to XH). The authors also greatly appreciate the assistance of American Journal Experts (AJE) editors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="6"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec id="s1"><title>Introduction</title><p>Neoadjuvant chemotherapy (NCT) directed to the breast and axilla followed by definitive surgical therapy is considered a standard treatment option for patients with locally advanced breast cancer <xref rid="pone.0111886-Mieog1" ref-type="bibr">[1]</xref>. However, the lack of an efficient method to predict treatment response and prognosis limits the clinical evaluation of patient eligibility.</p><p>Inflammation has long been associated with cancer development, and a chronic systemic inflammatory response has been clearly implicated in the progressive process and subsequent poor outcomes of breast cancer patients <xref rid="pone.0111886-Iyengar1" ref-type="bibr">[2]</xref>. Inflammation modifies the tumor biology and the quality of the immune response. Lymphocytes and monocytes are key immune cells in the inflammatory response and have been independently associated with the prognosis of various malignancies, such as breast cancer <xref rid="pone.0111886-Hornychov1" ref-type="bibr">[3]</xref>, gastric cancer <xref rid="pone.0111886-Bruckner1" ref-type="bibr">[4]</xref>, acute lymphoblastic leukemia <xref rid="pone.0111886-Sun1" ref-type="bibr">[5]</xref>, lymphoma <xref rid="pone.0111886-Wilcox1" ref-type="bibr">[6]</xref>, hepatocellular carcinoma <xref rid="pone.0111886-Chew1" ref-type="bibr">[7]</xref> and nasopharyngeal carcinoma <xref rid="pone.0111886-Koh1" ref-type="bibr">[8]</xref>, <xref rid="pone.0111886-Tibaldi1" ref-type="bibr">[9]</xref>.</p><p>Interestingly, the pretreatment lymphocyte-to-monocyte ratio (LMR) has been reported to be a prognostic factor for clinical outcomes in diffuse large B-cell lymphoma, Hodgkin&#x02019;s lymphoma and nasopharyngeal carcinoma <xref rid="pone.0111886-Wilcox1" ref-type="bibr">[6]</xref>, <xref rid="pone.0111886-Koh1" ref-type="bibr">[8]</xref>, <xref rid="pone.0111886-Bejon1" ref-type="bibr">[10]</xref>. Therefore, we hypothesized that lymphocytes, monocytes and LMR may also play an important role in breast cancer. We performed a large-scale retrospective cohort study on locally advanced breast cancer patients and investigated the prognostic value of pre-NCT LMR for the disease. To our knowledge, this is the first large-scale study on the association of LMR and breast cancer.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Study population</title><p>We collected data from 542 consecutive patients who were diagnosed with locally advanced breast cancer (T3/T4 and/or N2/N3 disease) and received NCT followed by radical surgery at the Fudan University Shanghai Cancer Center (Shanghai, China) from 2002 to 2011. Data on the medical history, patient characteristics, local and distant extent of disease (evaluated by chest CT, bone scan, abdominal ultrasound, bilateral mammography, breast ultrasound or breast MRI), and the blood chemistry before NCT were collected. Core needle biopsy (CNB) was performed to confirm the diagnosis of invasive breast cancer before NCT, and fine needle aspiration of palpable or ultrasound-detected lymph nodes was performed at the time of diagnosis. Patients who had received any treatment before NCT or who had metastatic disease before surgery were not eligible for this study. Other exclusion criteria included bilateral breast cancer, male breast cancer, and inflammatory breast cancer. All patients in this study underwent an NCT regimen consisting of NE (Navelbine 25 mg/m<sup>2</sup> on days 1 and 8 and epirubicin 60 mg/m<sup>2</sup> on day 1 every 3 weeks), CEF (cyclophosphamide 600 mg/m<sup>2</sup>, day 1; epirubicin 60 mg/m<sup>2</sup>, day 1; and 5-fluorouracil 600 mg/m<sup>2</sup>, day 1; every 3 weeks) or PC (paclitaxel, 80 mg/m<sup>2</sup>, and carboplatin area under the curve, 2 mg min/mL, on days 1, 8, and 15 of a 28-day cycle) for a median of four cycles (range, 3&#x02013;6 cycles). Mastectomy and axillary lymph node dissection were performed within 4 weeks of NCT completion, and additional cycles of chemotherapy were administered after the operation to complete a total of six cycles at the discretion of the treating physician. Radiotherapy was offered at the discretion of the treating radiation oncologist. Endocrine therapy was administered for patients with hormone receptor-positive tumors. Trastuzumab was recommended for patients with human epidermal receptor-2 (HER-2)-positive tumors in the adjuvant setting, but it was not included in any preoperative treatment. All patients were followed up every 3 months for the first year and then every 6 months until death. The last follow-up date was March 30, 2014 for all of the available patients. Our study was approved by the independent ethical committee/institutional review board of Fudan University Shanghai Cancer Center (Shanghai Cancer Center Ethical Committee). All patients provided written informed consent before inclusion in this study.</p></sec><sec id="s2b"><title>Pathology and immunohistochemistry</title><p>All pathological evaluations were performed at Fudan University Shanghai Cancer Center. The original histological determinations were obtained through CNB before enrollment. A pathological complete response (pCR) after NCT was defined as the absence of invasive carcinoma in the breast tissue and lymph nodes of the resected specimen. Residual ductal carcinoma in situ (DCIS) was included in the pCR group. Immunohistochemistry (IHC) analysis was performed on formalin-fixed, paraffin-embedded tissue sections using standard procedures for breast tumor specimens from CNB to evaluate the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) prior to NCT. The cut-off value for ER positivity and PR positivity was 1% positive tumor cells with nuclear staining. HER-2-positive status was defined as 3+ according to circumferential membrane-bound staining (HercepTest; Dako Cytomation) or amplification confirmed by florescent in situ hybridization. According to the 2011 St. Gallen consensus <xref rid="pone.0111886-Goldhirsch1" ref-type="bibr">[11]</xref>, we defined breast cancer subtypes as follows: luminal (ER and/or PR positive); HER-2 positive (ER and PR negative, HER-2 positive); or triple negative (TNBC; ER negative, PR negative, and HER-2 negative).</p></sec><sec id="s2c"><title>Laboratory data</title><p>As part of the physical examinations, peripheral blood was collected before treatment, and both peripheral lymphocytes and monocytes were counted using the automated hematology analyzer Sysmex XE-5000 (Sysmex, Kobe, Japan). The peripheral LMR was calculated as the ratio of absolute counts between peripheral lymphocytes and monocytes. Baseline LMR was established from peripheral blood samples taken immediately after breast cancer diagnosis and before the initiation of any treatment modality (pre-NCT LMR). All patients had no self-reported acute infections or hematologic disorders, indicating that the cell counts could represent the normal baseline value. Finally, we excluded 12 patients with missing pre-NCT lymphocyte counts and monocyte counts, which resulted in 542 patients remaining for further analyses.</p></sec><sec id="s2d"><title>Statistical analyses</title><p>Response was defined as complete response (CR), partial response (PR), or objective response (OR) (OR&#x0200a;=&#x0200a;CR+PR). Non-response was defined as stable disease (SD) or progressive disease (PD), according to WHO criteria <xref rid="pone.0111886-Miller1" ref-type="bibr">[12]</xref> or Response Evaluation Criteria in Solid Tumors (RECIST) criteria <xref rid="pone.0111886-Therasse1" ref-type="bibr">[13]</xref>. The pCR status was assessed after surgical resection of the remaining tumor and nodes, and pCR was defined as the absence of tumor cells or absence of persistent in situ disease and negative axillary lymph nodes. All samples were assessed by two individual pathologists at Fudan University Shanghai Cancer Center.</p><p>Receiver operating characteristic (ROC) curve analysis was performed to select the most appropriate cut-off points for the lymphocyte counts, monocyte counts and LMR to stratify patients at a high risk of malignancy-related death. The score with the maximum sensitivity and specificity was selected as the best cut-off value. The endpoints assessed was disease-free survival (DFS). DFS was defined as the duration between the date of diagnosis and the date of having any of the following events: invasive recurrence in local, regional, or distant sites; a new invasive breast cancer in the contralateral breast; any second (non-breast) malignancy; or death from any cause. These endpoints were analyzed and compared using the Kaplan-Meier method and the log-rank test. Categorical variables were compared using X<sup>2</sup> tests. Continuous variables, reported as lymphocyte counts, were compared using the Wilcoxon rank-sum test. Multivariate analyses with the Cox proportional hazards model were used to test independence, significance, and hazard discrimination. Covariates included in the model are given in the result tables as previously reported <xref rid="pone.0111886-Naranbhai1" ref-type="bibr">[14]</xref>. A two-tailed P value&#x0003c;0.05 was considered significant. The correlations between lymphocyte or monocyte counts and their ratio were evaluated by Spearman&#x02019;s rank correlation coefficient. The above analyses were performed using the SPSS software (version 19.0, SPSS Inc., Chicago, USA).</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Patient characteristics</title><p>The clinicopathological characteristics of the cohort study are summarized in <xref ref-type="table" rid="pone-0111886-t001">
<bold>Table 1</bold>
</xref>. All patients were female with a median age of 49 years at the time of diagnosis. After a mean follow-up time of 45.88 months, 51 of the 542 patients experienced disease recurrence. When the correlation between DFS and each clinicopathological variable was examined using univariate analysis, tumor status (HR&#x0200a;=&#x0200a;1.273; 95% CI, 1.081&#x02013;1.499; <italic>P</italic>&#x0200a;=&#x0200a;0.004; <xref ref-type="table" rid="pone-0111886-t002">
<bold>Table 2</bold>
</xref>), lymph node status (HR&#x0200a;=&#x0200a;1.154; 95% CI, 1.018&#x02013;1.310; <italic>P</italic>&#x0200a;=&#x0200a;0.026; <xref ref-type="table" rid="pone-0111886-t002">
<bold>Table 2</bold>
</xref>), grade status (HR&#x0200a;=&#x0200a;0.944; 95% CI, 0.905&#x02013;0.984; <italic>P</italic>&#x0200a;=&#x0200a;0.006; <xref ref-type="table" rid="pone-0111886-t002">
<bold>Table 2</bold>
</xref>) and NCT regimen (HR&#x0200a;=&#x0200a;0.777; 95% CI, 0.648&#x02013;0.932; <italic>P</italic>&#x0200a;=&#x0200a;0.006; <xref ref-type="table" rid="pone-0111886-t002">
<bold>Table 2</bold>
</xref>) were associated with a higher risk of recurrence and reached significance, as expected. Upon multivariate analysis, tumor status, lymph node status, pre-NCT hormone receptor status and pre-NCT HER2 status also exhibited significant association with DFS.</p><table-wrap id="pone-0111886-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0111886.t001</object-id><label>Table 1</label><caption><title>Characteristics of 542 locally advanced breast cancer according to ALC, AMC, and the ALC/AMC ratio.</title></caption><alternatives><graphic id="pone-0111886-t001-1" xlink:href="pone.0111886.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Overall</td><td align="left" rowspan="1" colspan="1">LMR&#x0003c;4.25</td><td align="left" rowspan="1" colspan="1">LMR&#x02265;4.25</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="left" rowspan="1" colspan="1">&#x02264;50</td><td align="left" rowspan="1" colspan="1">308</td><td align="left" rowspan="1" colspan="1">171</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">0.039<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;50</td><td align="left" rowspan="1" colspan="1">234</td><td align="left" rowspan="1" colspan="1">109</td><td align="left" rowspan="1" colspan="1">125</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Menopause status</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">320</td><td align="left" rowspan="1" colspan="1">179</td><td align="left" rowspan="1" colspan="1">141</td><td align="left" rowspan="1" colspan="1">0.019<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">221</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Tumor status</bold>
</td><td align="left" rowspan="1" colspan="1">1&#x02013;2</td><td align="left" rowspan="1" colspan="1">192</td><td align="left" rowspan="1" colspan="1">97</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">0.694<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3&#x02013;4</td><td align="left" rowspan="1" colspan="1">350</td><td align="left" rowspan="1" colspan="1">183</td><td align="left" rowspan="1" colspan="1">167</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lymph node status</bold>
</td><td align="left" rowspan="1" colspan="1">0&#x02013;1</td><td align="left" rowspan="1" colspan="1">400</td><td align="left" rowspan="1" colspan="1">199</td><td align="left" rowspan="1" colspan="1">201</td><td align="left" rowspan="1" colspan="1">0.135<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2&#x02013;3</td><td align="left" rowspan="1" colspan="1">142</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade</bold>
</td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0.273<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">174</td><td align="left" rowspan="1" colspan="1">99</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">III</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Stage</bold>
</td><td align="left" rowspan="1" colspan="1">I&#x02013;II</td><td align="left" rowspan="1" colspan="1">202</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">0.551<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">III&#x02013;IV</td><td align="left" rowspan="1" colspan="1">340</td><td align="left" rowspan="1" colspan="1">179</td><td align="left" rowspan="1" colspan="1">161</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HR</bold>
</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">123</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">0.094<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">312</td><td align="left" rowspan="1" colspan="1">149</td><td align="left" rowspan="1" colspan="1">163</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HER2</bold>
</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">375</td><td align="left" rowspan="1" colspan="1">199</td><td align="left" rowspan="1" colspan="1">176</td><td align="left" rowspan="1" colspan="1">0.179<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">147</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Breast cancer subtype</bold>
</td><td align="left" rowspan="1" colspan="1">Luminal</td><td align="left" rowspan="1" colspan="1">190</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">118</td><td align="left" rowspan="1" colspan="1">0.000<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">HER2</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TNBC</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Response</bold>
</td><td align="left" rowspan="1" colspan="1">SD+PD</td><td align="left" rowspan="1" colspan="1">332</td><td align="left" rowspan="1" colspan="1">172</td><td align="left" rowspan="1" colspan="1">160</td><td align="left" rowspan="1" colspan="1">0.005<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">OR</td><td align="left" rowspan="1" colspan="1">210</td><td align="left" rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Regimen</bold>
</td><td align="left" rowspan="1" colspan="1">NE</td><td align="left" rowspan="1" colspan="1">255</td><td align="left" rowspan="1" colspan="1">145</td><td align="left" rowspan="1" colspan="1">110</td><td align="left" rowspan="1" colspan="1">0.000<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">FEC</td><td align="left" rowspan="1" colspan="1">129</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">PC</td><td align="left" rowspan="1" colspan="1">158</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lymphocyte count (10<sup>9</sup>/L)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.57(0.1&#x02013;5)<xref ref-type="table-fn" rid="nt101">*</xref>
</td><td align="left" rowspan="1" colspan="1">1.48(0.1&#x02013;4.8)<xref ref-type="table-fn" rid="nt101">*</xref>
</td><td align="left" rowspan="1" colspan="1">1.67(0.6&#x02013;5.0)<xref ref-type="table-fn" rid="nt101">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.002<xref ref-type="table-fn" rid="nt103">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Monocyte count (10<sup>9</sup>/L)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.40(0.1&#x02013;2.1)<xref ref-type="table-fn" rid="nt101">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.54(0.1&#x02013;2.10)<xref ref-type="table-fn" rid="nt101">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.26(0.1&#x02013;0.7)<xref ref-type="table-fn" rid="nt101">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="nt103">a</xref>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>*Representing mean and range in the bracket; the mean LMR level was 5.01 (range, 0.13&#x02013;25);</p></fn><fn id="nt102"><label/><p>LMR, lymphocyte-to-monocyte ratio; HR, hormone status; HER2, human epithelial receptor 2.</p></fn><fn id="nt103"><label>a</label><p>Wilcoxon rank-sum test;</p></fn><fn id="nt104"><label>b</label><p>X2 test by two-sided Pearson&#x02019;s exact test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0111886-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0111886.t002</object-id><label>Table 2</label><caption><title>Univariate and multivariate analyses of LMR for DFS in locally advanced breast cancer.</title></caption><alternatives><graphic id="pone-0111886-t002-2" xlink:href="pone.0111886.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Univariate analysis</td><td colspan="2" align="left" rowspan="1">Multivariate analysis</td></tr><tr><td align="left" rowspan="1" colspan="1">Variable</td><td align="left" rowspan="1" colspan="1">HR (95% CI)</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="left" rowspan="1" colspan="1">HR (95% CI)</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">1.232(0.922&#x02013;1.645)</td><td align="left" rowspan="1" colspan="1">0.158</td><td align="left" rowspan="1" colspan="1">0.998(0.623, 1.601)</td><td align="left" rowspan="1" colspan="1">0.995</td></tr><tr><td align="left" rowspan="1" colspan="1">Menopause status</td><td align="left" rowspan="1" colspan="1">1.282(0.959, 1.714)</td><td align="left" rowspan="1" colspan="1">0.093</td><td align="left" rowspan="1" colspan="1">1.283(0.803, 2.050)</td><td align="left" rowspan="1" colspan="1">0.297</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor status</td><td align="left" rowspan="1" colspan="1">1.273(1.081&#x02013;1.499)</td><td align="left" rowspan="1" colspan="1">
<bold>0.004</bold>
</td><td align="left" rowspan="1" colspan="1">1.260(1.066, 1.490)</td><td align="left" rowspan="1" colspan="1">
<bold>0.007</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymph node status</td><td align="left" rowspan="1" colspan="1">1.154(1.018&#x02013;1.310)</td><td align="left" rowspan="1" colspan="1">
<bold>0.026</bold>
</td><td align="left" rowspan="1" colspan="1">1.429(1.037, 1.969)</td><td align="left" rowspan="1" colspan="1">
<bold>0.029</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade</td><td align="left" rowspan="1" colspan="1">0.944(0.905&#x02013;0.984)</td><td align="left" rowspan="1" colspan="1">
<bold>0.006</bold>
</td><td align="left" rowspan="1" colspan="1">0.955(0.911, 1.000)</td><td align="left" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" rowspan="1" colspan="1">Hormone receptor status</td><td align="left" rowspan="1" colspan="1">0.877(0.757&#x02013;1.016)</td><td align="left" rowspan="1" colspan="1">0.08</td><td align="left" rowspan="1" colspan="1">0.826(0.720, 0.947)</td><td align="left" rowspan="1" colspan="1">
<bold>0.006</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HER2 status</td><td align="left" rowspan="1" colspan="1">1.056(0.992&#x02013;1.124)</td><td align="left" rowspan="1" colspan="1">0.089</td><td align="left" rowspan="1" colspan="1">1.139(1.050, 1.236)</td><td align="left" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT regimen</td><td align="left" rowspan="1" colspan="1">0.777(0.648, 0.932)</td><td align="left" rowspan="1" colspan="1">
<bold>0.006</bold>
</td><td align="left" rowspan="1" colspan="1">0.927(0.752, 1.142)</td><td align="left" rowspan="1" colspan="1">0.475</td></tr><tr><td align="left" rowspan="1" colspan="1">LMR</td><td align="left" rowspan="1" colspan="1">0.678(0.506&#x02013;0.909)</td><td align="left" rowspan="1" colspan="1">
<bold>0.009</bold>
</td><td align="left" rowspan="1" colspan="1">0.680(0.505, 0.917)</td><td align="left" rowspan="1" colspan="1">
<bold>0.011</bold>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>Bold values are significant (P&#x0003c;0.05). DFS, disease-free survival; LMR, lymphocyte-to-monocyte ratio; HR, hazard ratio; HER2, human epidermal growth factor receptor-2; NCT, neoadjuvant chemotherapy.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>The cutoffs of LMR, ALC and AMC pre-NCT in locally advanced breast cancer</title><p>The mean counts of lymphocytes and monocytes were 1.57&#x000d7;10<sup>9</sup>/L (range, 0.1&#x02013;5&#x000d7;10<sup>9</sup>/L) and 0.40&#x000d7;10<sup>9</sup>/L (range, 0.1&#x02013;2.1&#x000d7;10<sup>9</sup>/L), respectively. The mean LMR level was 5.01 (range, 0.13&#x02013;25). ROC curve analysis was used to determine the optimal cut-off value for LMR. The LMR cut-off point for DFS was 4.25 (<xref ref-type="fig" rid="pone-0111886-g001">
<bold>Fig. 1A</bold>
</xref>), and all patients were divided into either high- (&#x02265;4.25) or low- (&#x0003c;4.25) LMR groups. Similarly, a lymphocyte count of 1.5&#x000d7;10<sup>9</sup>/L and monocyte count of 0.4&#x000d7;10<sup>9</sup>/L were selected as the optimal cut-off points for survival analyses. The mean lymphocyte count in the overall patients, the low-LMR group and the high-LMR group were 1.57, 1.48 and 1.67, respectively (<italic>P</italic>&#x0200a;=&#x0200a;0.002). The mean monocyte counts in the overall patients, the low-LMR group and the high-LMR group were 0.40, 0.54 and 0.26, respectively (<italic>P</italic>&#x0200a;=&#x0200a;0.001).</p><fig id="pone-0111886-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0111886.g001</object-id><label>Figure 1</label><caption><title>Elevated LMR indicates a favorable disease-free survival (DFS) in locally advanced breast cancer patients.</title><p>A. ROC curves assessing the cut-off of LMR for predicting the occurrence of disease events in the cohort study. B. Cumulative DFS curves of locally advanced breast cancer patients with high or low LMR (number of patients, 542, number of events, 186). C. Cumulative DFS curves of locally advanced breast cancer patients with high or low ALC (number of patients, 542, number of events, 186). D. Cumulative DFS curves of locally advanced breast cancer patients with high or low AMC (number of patients, 542, number of events, 186). <italic>LMR,</italic> lymphocyte-to-monocyte ratio; <italic>ALC,</italic> absolute lymphocyte count; <italic>AMC,</italic> absolute monocyte count; <italic>DFS,</italic> disease-free survival; <italic>ROC,</italic> receiver operating characteristic; <italic>AUC,</italic> area under the curve.</p></caption><graphic xlink:href="pone.0111886.g001"/></fig><p>In this cohort, an association between age, menopause status, breast cancer subtype, NCT regimen, NCT response and pre-NCT LMR was observed (<italic>P</italic>&#x0200a;=&#x0200a;0.039; <italic>P</italic>&#x0200a;=&#x0200a;0.019; <italic>P</italic>&#x0003c;0.001; <italic>P</italic>&#x0200a;=&#x0200a;0.005; <italic>P</italic>&#x0003c;0.001, respectively, <xref ref-type="table" rid="pone-0111886-t001">
<bold>Table 1</bold>
</xref>). An association of high LMR level (&#x02265;4.25) and improved ORR was found (<italic>P</italic>&#x0200a;=&#x0200a;0.005; <xref ref-type="table" rid="pone-0111886-t001">
<bold>Table 1</bold>
</xref>).</p></sec><sec id="s3c"><title>Elevated LMR indicates better clinical outcome in locally advanced breast cancer patients</title><p>To assess the clinical significance of pre-NCT LMR in locally advanced breast cancer, we analyzed the relationship between pre-NCT LMR and DFS. Both univariate and adjusted multivariate survival analyses revealed a significant difference between the high- and low-LMR groups. In this cohort, high-LMR cases exhibited a lower likelihood for disease events (HR&#x0200a;=&#x0200a;0.678; 95% CI, 0.506&#x02013;0.909; <italic>P</italic>&#x0200a;=&#x0200a;0.009; <xref ref-type="table" rid="pone-0111886-t002">
<bold>Table 2</bold>
</xref>) in univariate analysis and exhibited a similar trend upon multivariate analysis (HR&#x0200a;=&#x0200a;0.671; 95% CI, 0.499&#x02013;0.903; <italic>P</italic>&#x0200a;=&#x0200a;0.008; <xref ref-type="table" rid="pone-0111886-t002">
<bold>Table 2</bold>
</xref>). Additionally, patients with high LMR levels (&#x02265;4.25) generally exhibited a favorable DFS using Kaplan-Meier analysis (<italic>P</italic>&#x0200a;=&#x0200a;0.008; <xref ref-type="fig" rid="pone-0111886-g001">
<bold>Fig. 1B</bold>
</xref>). Interestingly, high lymphocyte counts (&#x02265;1.5&#x000d7;10<sup>9</sup>/L) showed borderline significance for better DFS (<italic>P</italic>&#x0200a;=&#x0200a;0.052), and low monocyte counts (&#x0003c;0.4&#x000d7;10<sup>9</sup>/L) were associated with improved DFS (<italic>P</italic>&#x0200a;=&#x0200a;0.010; <xref ref-type="fig" rid="pone-0111886-g001">
<bold>Fig. 1C, D</bold>
</xref>). Thus, these results strongly indicate that pre-NCT LMR is directly associated with recurrent disease for patients with locally advanced breast cancer.</p><p>In addition, both lymphocyte and monocyte counts were analyzed for their independence from other covariates in the COX model (<bold><xref ref-type="supplementary-material" rid="pone.0111886.s001">Table S1</xref></bold>). LMR is not included here, considering that LMR was derived as the ratio between the lymphocyte and the monocyte counts and related to lymphocyte count (Person&#x02019;s R&#x0200a;=&#x0200a;0.380, <italic>P</italic>&#x0003c;0.001) or monocyte count (Person&#x02019;s R&#x0200a;=&#x0200a;20.766, <italic>P</italic>&#x0003c;0.001) <xref rid="pone.0111886-Shen1" ref-type="bibr">[15]</xref>. The results showed that neither the lymphocyte nor the monocyte counts were independent factors for DFS in locally advanced breast cancer patients (<bold><xref ref-type="supplementary-material" rid="pone.0111886.s001">Table S1</xref></bold>).</p></sec></sec><sec id="s4"><title>Discussion</title><p>Accumulating studies have suggested a strong link between inflammation and cancer, and pretreatment peripheral inflammatory cells, including neutrophils, lymphocytes and monocytes, have been significantly associated with prognosis in different types of cancers <xref rid="pone.0111886-Tibaldi1" ref-type="bibr">[9]</xref>, <xref rid="pone.0111886-Schmidt1" ref-type="bibr">[16]</xref>, <xref rid="pone.0111886-Wilcox2" ref-type="bibr">[17]</xref>. As part of the functional relevance, inflammatory responses lead to chronic oxidative stress and generate oxygen free radicals, which have been shown to stimulate cancer initiation, promotion and progression <xref rid="pone.0111886-Hussain1" ref-type="bibr">[18]</xref>, <xref rid="pone.0111886-Nakamura1" ref-type="bibr">[19]</xref>, <xref rid="pone.0111886-Salim1" ref-type="bibr">[20]</xref>. Moreover, tumor-associated macrophages (TAMs), an important component of inflammatory infiltrating leukocytes, may interact with tumor cells to promote tumor development by producing various cytokines and chemokines. We performed a large-scale cohort study on locally advanced breast cancer patients who received NCT to evaluate the prognostic values of peripheral lymphocytes and monocytes, together with other clinical factors. Our results confirmed previous findings that factors such as T, N, grade and overall stage were associated with a favorable prognosis for breast cancer patients. More importantly, we found that an elevated LMR was significantly associated with better ORR and DFS and, independent of other variables, was able to predict patient prognosis for locally advanced breast cancer after NCT.</p><p>Interestingly, there was a correlation between LMR and treatment regimen (<italic>P</italic>&#x0003c;0.001, <xref ref-type="table" rid="pone-0111886-t001">
<bold>Table 1</bold>
</xref>). When the correlation between DFS and each clinicopathological variable was examined using univariate analysis, NCT regimen (HR&#x0200a;=&#x0200a;0.777; 95% CI, 0.648&#x02013;0.932; <italic>P</italic>&#x0200a;=&#x0200a;0.006; <xref ref-type="table" rid="pone-0111886-t002">
<bold>Table 2</bold>
</xref>) was associated with a higher risk of recurrence and reached significance. However, multivariate analysis did not (HR&#x0200a;=&#x0200a;0.927; 95% CI, 0.752&#x02013;1.142; <italic>P</italic>&#x0200a;=&#x0200a;0.475; <xref ref-type="table" rid="pone-0111886-t002">
<bold>Table 2</bold>
</xref>). One of the reason may be a relatively limited number of patients was used. The other could be the complex function of lymphocyte and monocyte in cancer progression. Further pre-clinical and clinical study should attempt to confirm our conclusions and clarify the underlying mechanism. For the first time, we jointly considered the counts of lymphocytes and monocytes and assessed the prognostic role of LMR for clinical outcomes in large operable or locally advanced breast cancer after NCT. However, the association of LMR with cancer survival has been reported in classical Hodgkin&#x02019;s lymphoma (cHL), diffuse large B-cell lymphoma and NPC <xref rid="pone.0111886-Bejon1" ref-type="bibr">[10]</xref>, <xref rid="pone.0111886-Porrata1" ref-type="bibr">[21]</xref>, <xref rid="pone.0111886-Li1" ref-type="bibr">[22]</xref>. We found that an elevated LMR is associated with ORR in breast cancer patients receiving NCT. In addition, we found that an elevated LMR not only had a strong correlation with better DFS but was also an independent prognostic factor for survival in the multivariate analysis under the Cox model. These data support previous findings on cHL and NPC, where an elevated LMR had a significantly better OS and DFS <xref rid="pone.0111886-Bejon1" ref-type="bibr">[10]</xref>, <xref rid="pone.0111886-Porrata1" ref-type="bibr">[21]</xref>. Similar results were also found in diffuse large B-cell lymphoma, which is another hematological malignancy. Together, our findings suggest that these immune cells may play similar roles in breast cancer and hematological malignancies.</p><p>Interestingly, univariate analysis revealed that a high lymphocyte count (&#x02265;1.5&#x000d7;10<sup>9</sup>/L) showed borderline significance for better DFS (<italic>P</italic>&#x0200a;=&#x0200a;0.054), and a low monocyte count (&#x0003c;0.4&#x000d7;10<sup>9</sup>/L) was associated with a better DFS (<italic>P</italic>&#x0200a;=&#x0200a;0.010; <bold><xref ref-type="supplementary-material" rid="pone.0111886.s001">Table S1</xref></bold>). These data were inconsistent with previous findings in breast cancer and other cancers, such as ovarian cancer, where a high lymphocyte count was reported as an independent favorable prognostic factor <xref rid="pone.0111886-Bishara1" ref-type="bibr">[23]</xref>, <xref rid="pone.0111886-Noh1" ref-type="bibr">[24]</xref>, <xref rid="pone.0111886-He1" ref-type="bibr">[25]</xref>. By contrast, pretreatment lymphopenia has been considered an indicator for poor outcomes <xref rid="pone.0111886-Porrata2" ref-type="bibr">[26]</xref>, <xref rid="pone.0111886-Saroha1" ref-type="bibr">[27]</xref>. The favorable role of lymphocytes appears biologically plausible. Lymphocytes are crucial components of host immunity that are important in the destruction of residual tumor cells and related micrometastases <xref rid="pone.0111886-Fogar1" ref-type="bibr">[28]</xref>, <xref rid="pone.0111886-Sarraf1" ref-type="bibr">[29]</xref>, and infiltrating lymphocytes can activate an effective antitumor cellular immune response <xref rid="pone.0111886-Rabinowich1" ref-type="bibr">[30]</xref>. Moreover, T lymphocytes could help drive cancer cells towards apoptosis due to the state of chronic activation in cancer patients <xref rid="pone.0111886-Dworacki1" ref-type="bibr">[31]</xref> and lead to the death of cancer cells in response to chemotherapy by presenting tumor-associated antigens to immune cells <xref rid="pone.0111886-Youn1" ref-type="bibr">[32]</xref>, <xref rid="pone.0111886-Apetoh1" ref-type="bibr">[33]</xref>.</p></sec><sec id="s5"><title>Conclusions</title><p>Taken together, we are the first to demonstrate that pre-NCT elevated peripheral blood LMR predicts favorable response and prognosis in locally advanced breast cancer. This biomarker was directly derived from routine blood cell counts and can be easily applied in the clinical setting. We acknowledge that this finding is limited to a retrospective study in a single center, and thus, further studies performed in a multicenter or prospective manner are necessary to validate the clinical usage of pre-NCT LMR as a prognostic marker for locally advanced breast cancer.</p></sec><sec id="s6"><title>Ethical Standards</title><p>Informed consent was signed by each participant, and appropriate ethical committee approval was obtained. The experiments comply with the current laws of China.</p></sec><sec sec-type="supplementary-material" id="s7"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0111886.s001"><label>Table S1</label><caption><p>
<bold>Multivariate analysis of independent prognostic factors (n&#x0200a;=&#x0200a;542).</bold>
</p><p>(DOCX)</p></caption><media xlink:href="pone.0111886.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0111886-Mieog1"><label>1</label><mixed-citation publication-type="other">Mieog JS, van der Hage JA, van de Velde CJ. (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev CD005002.</mixed-citation></ref><ref id="pone.0111886-Iyengar1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Iyengar</surname><given-names>NM</given-names></name>, <name><surname>Hudis</surname><given-names>CA</given-names></name>, <name><surname>Dannenberg</surname><given-names>AJ</given-names></name> (<year>2013</year>) <article-title>Obesity and inflammation: new insights into breast cancer development and progression</article-title>. <source>Am Soc Clin Oncol Educ Book</source>
<volume>33</volume>: <fpage>46</fpage>&#x02013;<lpage>51</lpage>.</mixed-citation></ref><ref id="pone.0111886-Hornychov1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Hornychov&#x000e1;</surname><given-names>H</given-names></name>, <name><surname>Melichar</surname><given-names>B</given-names></name>, <name><surname>Tom&#x00161;ov&#x000e1;</surname><given-names>M</given-names></name>, <name><surname>Mergancov&#x000e1;</surname><given-names>J</given-names></name>, <name><surname>Urminsk&#x000e1;</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma</article-title>. <source>Cancer Investigation</source>
<volume>26</volume>: <fpage>1024</fpage>&#x02013;<lpage>1031</lpage>.<pub-id pub-id-type="pmid">19093260</pub-id></mixed-citation></ref><ref id="pone.0111886-Bruckner1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Bruckner</surname><given-names>HW</given-names></name>, <name><surname>Lavin</surname><given-names>PT</given-names></name>, <name><surname>Plaxe</surname><given-names>SC</given-names></name>, <name><surname>Storch</surname><given-names>JA</given-names></name>, <name><surname>Livstone</surname><given-names>EM</given-names></name> (<year>1982</year>) <article-title>Absolute granulocyte, lymphocyte, and moncyte counts. Useful determinants of prognosis for patients with metastatic cancer of the stomach</article-title>. <source>JAMA</source>
<volume>247</volume>: <fpage>1004</fpage>&#x02013;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">7035703</pub-id></mixed-citation></ref><ref id="pone.0111886-Sun1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Sun</surname><given-names>D</given-names></name>, <name><surname>Elson</surname><given-names>P</given-names></name>, <name><surname>Liedtke</surname><given-names>M</given-names></name>, <name><surname>Medeiros</surname><given-names>BC</given-names></name>, <name><surname>Earl</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia</article-title>. <source>Am J Hematol</source>
<volume>87</volume>: <fpage>957</fpage>&#x02013;<lpage>960</lpage>.<pub-id pub-id-type="pmid">22729847</pub-id></mixed-citation></ref><ref id="pone.0111886-Wilcox1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Wilcox</surname><given-names>RA</given-names></name>, <name><surname>Ristow</surname><given-names>K</given-names></name>, <name><surname>Habermann</surname><given-names>TM</given-names></name>, <name><surname>Inwards</surname><given-names>DJ</given-names></name>, <name><surname>Micallef</surname><given-names>IN</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma</article-title>. <source>Leukemia</source>
<volume>25</volume>: <fpage>1502</fpage>&#x02013;<lpage>1509</lpage>.<pub-id pub-id-type="pmid">21606957</pub-id></mixed-citation></ref><ref id="pone.0111886-Chew1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Chew</surname><given-names>V</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Lee</surname><given-names>D</given-names></name>, <name><surname>Loh</surname><given-names>E</given-names></name>, <name><surname>Lee</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma</article-title>. <source>Gut</source>
<volume>61</volume>: <fpage>427</fpage>&#x02013;<lpage>438</lpage>.<pub-id pub-id-type="pmid">21930732</pub-id></mixed-citation></ref><ref id="pone.0111886-Koh1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Koh</surname><given-names>YW</given-names></name>, <name><surname>Kang</surname><given-names>HJ</given-names></name>, <name><surname>Park</surname><given-names>C</given-names></name>, <name><surname>Yoon</surname><given-names>DH</given-names></name>, <name><surname>Kim</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages</article-title>. <source>Oncologist</source>
<volume>17</volume>: <fpage>871</fpage>&#x02013;<lpage>880</lpage>.<pub-id pub-id-type="pmid">22588324</pub-id></mixed-citation></ref><ref id="pone.0111886-Tibaldi1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Tibaldi</surname><given-names>C</given-names></name>, <name><surname>Vasile</surname><given-names>E</given-names></name>, <name><surname>Bernardini</surname><given-names>I</given-names></name>, <name><surname>Orlandini</surname><given-names>C</given-names></name>, <name><surname>Andreuccetti</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model</article-title>. <source>J Cancer Res Clin Oncol</source>
<volume>134</volume>: <fpage>1143</fpage>&#x02013;<lpage>1149</lpage>.<pub-id pub-id-type="pmid">18347812</pub-id></mixed-citation></ref><ref id="pone.0111886-Bejon1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Bejon</surname><given-names>P</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Jiang</surname><given-names>R</given-names></name>, <name><surname>Liu</surname><given-names>W-S</given-names></name>, <name><surname>Liu</surname><given-names>Q</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>A Large Cohort Study Reveals the Association of Elevated Peripheral Blood Lymphocyte-to-Monocyte Ratio with Favorable Prognosis in Nasopharyngeal Carcinoma</article-title>. <source>PLoS ONE</source>
<volume>8</volume>: <fpage>e83069</fpage>.<pub-id pub-id-type="pmid">24386144</pub-id></mixed-citation></ref><ref id="pone.0111886-Goldhirsch1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Goldhirsch</surname><given-names>A</given-names></name>, <name><surname>Wood</surname><given-names>WC</given-names></name>, <name><surname>Coates</surname><given-names>AS</given-names></name>, <name><surname>Gelber</surname><given-names>RD</given-names></name>, <name><surname>Thurlimann</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Strategies for subtypes&#x02013;dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011</article-title>. <source>Ann Oncol</source>
<volume>22</volume>: <fpage>1736</fpage>&#x02013;<lpage>1747</lpage>.<pub-id pub-id-type="pmid">21709140</pub-id></mixed-citation></ref><ref id="pone.0111886-Miller1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Miller</surname><given-names>AB</given-names></name>, <name><surname>Hoogstraten</surname><given-names>B</given-names></name>, <name><surname>Staquet</surname><given-names>M</given-names></name>, <name><surname>Winkler</surname><given-names>A</given-names></name> (<year>1981</year>) <article-title>Reporting results of cancer treatment</article-title>. <source>Cancer</source>
<volume>47</volume>: <fpage>207</fpage>&#x02013;<lpage>214</lpage>.<pub-id pub-id-type="pmid">7459811</pub-id></mixed-citation></ref><ref id="pone.0111886-Therasse1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Therasse</surname><given-names>P</given-names></name>, <name><surname>Arbuck</surname><given-names>SG</given-names></name>, <name><surname>Eisenhauer</surname><given-names>EA</given-names></name>, <name><surname>Wanders</surname><given-names>J</given-names></name>, <name><surname>Kaplan</surname><given-names>RS</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title>. <source>J Natl Cancer Inst</source>
<volume>92</volume>: <fpage>205</fpage>&#x02013;<lpage>216</lpage>.<pub-id pub-id-type="pmid">10655437</pub-id></mixed-citation></ref><ref id="pone.0111886-Naranbhai1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Naranbhai</surname><given-names>V</given-names></name>, <name><surname>Hill</surname><given-names>AV</given-names></name>, <name><surname>Abdool Karim</surname><given-names>SS</given-names></name>, <name><surname>Naidoo</surname><given-names>K</given-names></name>, <name><surname>Abdool Karim</surname><given-names>Q</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy</article-title>. <source>J Infect Dis</source>
<volume>209</volume>: <fpage>500</fpage>&#x02013;<lpage>509</lpage>.<pub-id pub-id-type="pmid">24041796</pub-id></mixed-citation></ref><ref id="pone.0111886-Shen1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Shen</surname><given-names>GP</given-names></name>, <name><surname>Xu</surname><given-names>FH</given-names></name>, <name><surname>He</surname><given-names>F</given-names></name>, <name><surname>Ruan</surname><given-names>HL</given-names></name>, <name><surname>Cui</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Pretreatment lifestyle behaviors as survival predictors for patients with nasopharyngeal carcinoma</article-title>. <source>PLoS ONE</source>
<volume>7</volume>: <fpage>e36515</fpage>.<pub-id pub-id-type="pmid">22590554</pub-id></mixed-citation></ref><ref id="pone.0111886-Schmidt1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Schmidt</surname><given-names>H</given-names></name>, <name><surname>Bastholt</surname><given-names>L</given-names></name>, <name><surname>Geertsen</surname><given-names>P</given-names></name>, <name><surname>Christensen</surname><given-names>IJ</given-names></name>, <name><surname>Larsen</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model</article-title>. <source>Br J Cancer</source>
<volume>93</volume>: <fpage>273</fpage>&#x02013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">16052222</pub-id></mixed-citation></ref><ref id="pone.0111886-Wilcox2"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Wilcox</surname><given-names>RA</given-names></name>, <name><surname>Ristow</surname><given-names>K</given-names></name>, <name><surname>Habermann</surname><given-names>TM</given-names></name>, <name><surname>Inwards</surname><given-names>DJ</given-names></name>, <name><surname>Micallef</surname><given-names>IN</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma</article-title>. <source>Leuk Lymphoma</source>
<volume>53</volume>: <fpage>575</fpage>&#x02013;<lpage>580</lpage>.<pub-id pub-id-type="pmid">22098403</pub-id></mixed-citation></ref><ref id="pone.0111886-Hussain1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Hussain</surname><given-names>SP</given-names></name>, <name><surname>Aguilar</surname><given-names>F</given-names></name>, <name><surname>Amstad</surname><given-names>P</given-names></name>, <name><surname>Cerutti</surname><given-names>P</given-names></name> (<year>1994</year>) <article-title>Oxy-radical induced mutagenesis of hotspot codons 248 and 249 of the human p53 gene</article-title>. <source>Oncogene</source>
<volume>9</volume>: <fpage>2277</fpage>&#x02013;<lpage>2281</lpage>.<pub-id pub-id-type="pmid">8036011</pub-id></mixed-citation></ref><ref id="pone.0111886-Nakamura1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Nakamura</surname><given-names>Y</given-names></name>, <name><surname>Gindhart</surname><given-names>TD</given-names></name>, <name><surname>Winterstein</surname><given-names>D</given-names></name>, <name><surname>Tomita</surname><given-names>I</given-names></name>, <name><surname>Seed</surname><given-names>JL</given-names></name>, <etal>et al</etal> (<year>1988</year>) <article-title>Early superoxide dismutase-sensitive event promotes neoplastic transformation in mouse epidermal JB6 cells</article-title>. <source>Carcinogenesis</source>
<volume>9</volume>: <fpage>203</fpage>&#x02013;<lpage>207</lpage>.<pub-id pub-id-type="pmid">2827903</pub-id></mixed-citation></ref><ref id="pone.0111886-Salim1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Salim</surname><given-names>AS</given-names></name> (<year>1993</year>) <article-title>The permissive role of oxygen-derived free radicals in the development of colonic cancer in the rat. A new theory for carcinogenesis</article-title>. <source>Int J Cancer</source>
<volume>53</volume>: <fpage>1031</fpage>&#x02013;<lpage>1035</lpage>.<pub-id pub-id-type="pmid">8473044</pub-id></mixed-citation></ref><ref id="pone.0111886-Porrata1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Porrata</surname><given-names>LF</given-names></name>, <name><surname>Inwards</surname><given-names>DJ</given-names></name>, <name><surname>Ansell</surname><given-names>SM</given-names></name>, <name><surname>Micallef</surname><given-names>IN</given-names></name>, <name><surname>Johnston</surname><given-names>PB</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation</article-title>. <source>Bone Marrow Res</source>
<volume>2013</volume>: <fpage>658371</fpage>.<pub-id pub-id-type="pmid">23710362</pub-id></mixed-citation></ref><ref id="pone.0111886-Li1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Li</surname><given-names>ZM</given-names></name>, <name><surname>Huang</surname><given-names>JJ</given-names></name>, <name><surname>Xia</surname><given-names>Y</given-names></name>, <name><surname>Sun</surname><given-names>J</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP</article-title>. <source>PLoS ONE</source>
<volume>7</volume>: <fpage>e41658</fpage>.<pub-id pub-id-type="pmid">22911837</pub-id></mixed-citation></ref><ref id="pone.0111886-Bishara1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Bishara</surname><given-names>S</given-names></name>, <name><surname>Griffin</surname><given-names>M</given-names></name>, <name><surname>Cargill</surname><given-names>A</given-names></name>, <name><surname>Bali</surname><given-names>A</given-names></name>, <name><surname>Gore</surname><given-names>ME</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>
<volume>138</volume>: <fpage>71</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">17644243</pub-id></mixed-citation></ref><ref id="pone.0111886-Noh1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Noh</surname><given-names>H</given-names></name>, <name><surname>Eomm</surname><given-names>M</given-names></name>, <name><surname>Han</surname><given-names>A</given-names></name> (<year>2013</year>) <article-title>Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients</article-title>. <source>J Breast Cancer</source>
<volume>16</volume>: <fpage>55</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">23593082</pub-id></mixed-citation></ref><ref id="pone.0111886-He1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>He</surname><given-names>JR</given-names></name>, <name><surname>Shen</surname><given-names>GP</given-names></name>, <name><surname>Ren</surname><given-names>ZF</given-names></name>, <name><surname>Qin</surname><given-names>H</given-names></name>, <name><surname>Cui</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma</article-title>. <source>Head Neck</source>
<volume>34</volume>: <fpage>1769</fpage>&#x02013;<lpage>1776</lpage>.<pub-id pub-id-type="pmid">22318781</pub-id></mixed-citation></ref><ref id="pone.0111886-Porrata2"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Porrata</surname><given-names>LF</given-names></name>, <name><surname>Ristow</surname><given-names>K</given-names></name>, <name><surname>Colgan</surname><given-names>JP</given-names></name>, <name><surname>Habermann</surname><given-names>TM</given-names></name>, <name><surname>Witzig</surname><given-names>TE</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma</article-title>. <source>Haematologica</source>
<volume>97</volume>: <fpage>262</fpage>&#x02013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">21993683</pub-id></mixed-citation></ref><ref id="pone.0111886-Saroha1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Saroha</surname><given-names>S</given-names></name>, <name><surname>Uzzo</surname><given-names>RG</given-names></name>, <name><surname>Plimack</surname><given-names>ER</given-names></name>, <name><surname>Ruth</surname><given-names>K</given-names></name>, <name><surname>Al-Saleem</surname><given-names>T</given-names></name> (<year>2013</year>) <article-title>Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma</article-title>. <source>J Urol</source>
<volume>189</volume>: <fpage>454</fpage>&#x02013;<lpage>461</lpage>.<pub-id pub-id-type="pmid">23041457</pub-id></mixed-citation></ref><ref id="pone.0111886-Fogar1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Fogar</surname><given-names>P</given-names></name>, <name><surname>Sperti</surname><given-names>C</given-names></name>, <name><surname>Basso</surname><given-names>D</given-names></name>, <name><surname>Sanzari</surname><given-names>MC</given-names></name>, <name><surname>Greco</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome</article-title>. <source>Pancreas</source>
<volume>32</volume>: <fpage>22</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">16340740</pub-id></mixed-citation></ref><ref id="pone.0111886-Sarraf1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Sarraf</surname><given-names>KM</given-names></name>, <name><surname>Belcher</surname><given-names>E</given-names></name>, <name><surname>Raevsky</surname><given-names>E</given-names></name>, <name><surname>Nicholson</surname><given-names>AG</given-names></name>, <name><surname>Goldstraw</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer</article-title>. <source>J Thorac Cardiovasc Surg</source>
<volume>137</volume>: <fpage>425</fpage>&#x02013;<lpage>428</lpage>.<pub-id pub-id-type="pmid">19185164</pub-id></mixed-citation></ref><ref id="pone.0111886-Rabinowich1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Rabinowich</surname><given-names>H</given-names></name>, <name><surname>Cohen</surname><given-names>R</given-names></name>, <name><surname>Bruderman</surname><given-names>I</given-names></name>, <name><surname>Steiner</surname><given-names>Z</given-names></name>, <name><surname>Klajman</surname><given-names>A</given-names></name> (<year>1987</year>) <article-title>Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes</article-title>. <source>Cancer Res</source>
<volume>47</volume>: <fpage>173</fpage>&#x02013;<lpage>177</lpage>.<pub-id pub-id-type="pmid">3491673</pub-id></mixed-citation></ref><ref id="pone.0111886-Dworacki1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Dworacki</surname><given-names>G</given-names></name>, <name><surname>Meidenbauer</surname><given-names>N</given-names></name>, <name><surname>Kuss</surname><given-names>I</given-names></name>, <name><surname>Hoffmann</surname><given-names>TK</given-names></name>, <name><surname>Gooding</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma</article-title>. <source>Clin Cancer Res</source>
<volume>7</volume>: <fpage>947s</fpage>&#x02013;<lpage>957s</lpage>.<pub-id pub-id-type="pmid">11300496</pub-id></mixed-citation></ref><ref id="pone.0111886-Youn1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Youn</surname><given-names>JI</given-names></name>, <name><surname>Collazo</surname><given-names>M</given-names></name>, <name><surname>Shalova</surname><given-names>IN</given-names></name>, <name><surname>Biswas</surname><given-names>SK</given-names></name>, <name><surname>Gabrilovich</surname><given-names>DI</given-names></name> (<year>2012</year>) <article-title>Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice</article-title>. <source>J Leukoc Biol</source>
<volume>91</volume>: <fpage>167</fpage>&#x02013;<lpage>181</lpage>.<pub-id pub-id-type="pmid">21954284</pub-id></mixed-citation></ref><ref id="pone.0111886-Apetoh1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Apetoh</surname><given-names>L</given-names></name>, <name><surname>Ghiringhelli</surname><given-names>F</given-names></name>, <name><surname>Tesniere</surname><given-names>A</given-names></name>, <name><surname>Obeid</surname><given-names>M</given-names></name>, <name><surname>Ortiz</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy</article-title>. <source>Nat Med</source>
<volume>13</volume>: <fpage>1050</fpage>&#x02013;<lpage>1059</lpage>.<pub-id pub-id-type="pmid">17704786</pub-id></mixed-citation></ref></ref-list></back></article>